Fueled by soaring demand for its GLP-1 weight-loss drugs, Eli Lilly saw its fourth-quarter profits climb. The pharmaceutical giant is benefiting from the increasing popularity of treatments like Mounjaro and Zepbound, which have become blockbusters in the market. These medications are transforming how obesity and related conditions are addressed, driving substantial revenue growth for the company.